We recently reported that physiological concentrations of 17β-estradiol partially down-regulate cardiac rapidly-activating delayed rectifier K + currents (hERG currents) independently of estrogen-receptor signaling. To determine if other estrogens have the same effect as that of 17β-estradiol, we investigated receptor-independent effects of estrone, estrone 3-sulfate, and estriol on hERG currents in patch-clamped estrogen-negative HEK293 cells. Only estrone 3sulfate partially suppressed hERG currents in a receptor-independent manner by modifying the gating. The concentration-dependence of estrone 3-sulfate revealed that physiological levels of circulating estrone 3-sulfate can modulate hERG currents to the maximal extent in both women and men at any age.
Female gender is an independent risk factor for development of torsade de pointes (TdP) not only in congenital long QT syndromes (LQTS) but also in acquired LQTS (1, 2) resulting mostly from blockade of the human ether-a-go-go-related gene (hERG) channel (3) . Actually 65% -75% of drug-induced TdP occurs in women, and is thought to be associated, at least in part, with longer baseline rate-corrected QT intervals (QT C ) in women than those in men (4) .
There is increasing evidence that effects of sex hormones on the ionic process underlying cardiac repolarization are important determinants of the sexrelated differences (5 -7) . The shortening of the QT interval by testosterone and / or progesterone have been suggested from clinical reports and model studies. In contrast, some clinical studies imply that estrogen can increase the risks of drug-induced TdP in women. In healthy premenopausal women volunteers, the susceptibility of drug-induced QT C prolongation is exaggerated in the late follicular phase where estrogen level is the highest (8) . Baseline QT C in postmenopausal women who are currently taking an only estrogen-replacement therapy is slightly but significantly longer compared with the control population (9) . In addition to the well-characterized influences of estrogen in cardiac repolarization concerning hormonal genomic actions (1, 10) , we recently found that the physiological levels of 17β-estradiol (E2), the bioactive estrogen, acutely downregulates the hERG channel, resulting in QT C prolongation (11) . Such effects of E2 are independent of the estrogen-receptor signaling, and interaction between aromatic rings of E2 and F656 hERG may be important for the effect (11) .
Despite of these intensive studies, underlying mechanisms for a contribution of estrogen to arrhythmogenicity remains to be unclear: for example, It has been shown that propensity to drug-induced TdP does not decline after menopause in women who have very low levels of endogenous ovarian estrogen including E2 (12) . Because the hERG suppression by E2 is independent of the estrogen-receptor signaling (11) , it is possible that other estrogens suppress hERG currents as E2 does. However there have been no reports as to the ability of other estrogens to modulate hERG currents acutely.
To determine if estrogens other than E2 can modulate † These two authors equally contributed to this work. *Corresponding author. junkokuro.bip@mri.tmd.ac.jp Published online in J-STAGE on January 8, 2009 (in advance) doi: 10.1254/jphs.08257SC hERG currents independently of the estrogen-receptor signaling, we here investigated the effects of major circulating estrogens, estrone (E1), estrone 3-sulfate sodium salt (E1S), and estriol (E3) ( Fig. 1 ), on hERG currents recorded from human embryonic kidney (HEK) 293 cells expressing hERG stably and no intrinsic estrogen receptors (11) .
Methods are described in detail elsewhere (11) . In brief, HEK 293 cells stably expressing hERG were cultured in phenol red-free D-MEM supplemented with 10% charcoal-treated FBS and 0.8% geneticin. HERG channel currents were recorded at room temperature (22 ± 1°C) by using the perforated patch-clamp technique with an Axopatch 200B amplifier (Axon Instruments, USA). The control bath solution contained 132 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl 2 , 2 mM , and E3 at 10 nM (c) on hERG currents recorded at −40 mV after +20-mV test pulses as shown above the traces. Shown are representative traces before (control) and after the external application of estrogens for 6 min and after washout of E1S for 3 min (washout, gray line). Chemical structures of estrogens are shown above the traces. B: Time courses of the effects of E1S at 0.3 nM (closed squares, n = 10), E1 at 10 nM (open circles, n = 4), and E3 at 10 nM (closed triangles, n = 5). Plots (means ± S.E.M.) are shown as ratios of the peak tail amplitudes just before the application of estrogens (control at time zero). C: Concentration-dependent curves for effects of E1S (closed squares), E1 (open circles), and E3 (closed triangles) on hERG current amplitudes. HERG currents were recorded as in panel A. Each concentration of the estrogens was applied for more than 5 min until its effect became stable. Plots (mean ± S.E.M.) were normalized tail amplitudes before the washout in the presence of estrogens relative to the values just before the drug application (control). One or two concentrations were tested in a single cell. Numbers of experiments for the E1S application are indicated in the plot as numbers in parentheses. The plots for E1 and E3 were each obtained from 4 -5 experiments. The curve for E1S represents the best fit of data points with Langmuir's isotherm (see text). Kd = 0.03 nM and A = 0.20. (11).
To investigate effects of estrogens on hERG current amplitudes, hERG channel tail-current amplitude was monitored at 0.1 Hz by analysis of peak deactivating tail current recorded at −40 mV after 2-s depolarizing test pulses to +20 mV from a holding potential of −80 mV as described previously by us (11) . Using this voltage protocol, averaged peak tail-current amplitude before the application of estrogens was 32.6 ± 9.8 pA / pF (n = 14), which is much larger than those in guinea-pig ventricular myocytes [about 0.2 pA / pF (11)]. As shown in Fig. 1: A and B , a physiological concentration of E1S (0.3 nM) suppressed hERG tail currents by about 20% within 5 min, and then the wash-out of E1S only partially recovered the inhibition (n = 10). This result indicates that E1S inhibits hERG currents in a receptorindependent manner, just like E2 does (11) . The partial inhibition by E1S showed a concentration-dependence, and the data were best fitted with Langmuir's isotherm: Y (ratio of control) = A*K d / (K d + [drug]) + 1 − A, where K d is the dissociation equilibrium constant; A, drug-sensitive component (ratio); and [drug], concentration of E1S,
Fig. 2. Effects of E1S on gating properties of the hERG channel. A:
The effect of E1S on the voltage-dependent hERG activation. hERG activation was studied as described in the text. Representative traces from a single cell before (upper left) and after (upper right) 5-min application of E1S (0.3 nM). Normalized peaks of tail currents tail currents (lower) were plotted as function of the hERG activation (n = 8). *P<0.05, ANOVA with repeated measures. B: The effect of E1S on the hERG deactivation process. After +40-mV pulses were applied, deactivating tail currents were elicited by 3-s test pulses to various potentials. Fast (τfast, upper) and slow (τslow, middle) time constants of deactivation are plotted against the test potentials before (the control), 5-min after application of E1S at 0.3 nM, and 5-min after washout (n = 8). Normalized tail currents at −40 mV are averaged in each condition (lower). *P<0.05, **P<0.01, ***P<0.001, ANOVA with repeated measures. resulting in a K d value of 0.03 nM and an A of 0.20 (Fig. 1C) . In contrast, very high concentration of E1 (10 nM) and E3 (10 nM) showed no significant effects on hERG currents recorded by the same experimental protocol (Fig. 1: A and B , n = 4 -5). Figure 1C confirmed that there was no effect of wide concentration ranges of E1 and E3 on tail hERG currents.
Does E1S modify gating properties of the hERG channel? To address this question, we next investigated effects of E1S on the hERG activation and the hERG deactivation kinetics. Activation of hERG currents were studied by analysis of deactivating tail currents recorded at −40 mV after a series of 2-s activating pulses (10-mV increments) from a holding potential of −80 mV. Pulse frequency was 0.1 Hz. Activation curves were shown as plots of normalized tail currents to the maximum extent vs. activating test pulse voltage. Figure 2A shows that the application of E1S shifted the activation curve to the positive direction (n = 8). The activation curves were analyzed with a fit of each data value to the Boltzman equation:
where G / G max is normalized chord conductance at V m to the maximum chord conductance, V 1/ 2 is the potential where the conductance is half-maximally activated, and k is the slop factor. Table 1 , which summarizes the analysis of the data, shows that the 5min application of E1S did not affect the maximum hERG current density but significantly affected voltagedependence of the activation. The table shows that the wash-out of E1S for 5 min did not recover the shift of V 1 / 2 , although there was a slight trend of recovery of the shift. To test if E1S modifies the hERG deactivation kinetics, deactivating tail currents after 1-s activating pulses to +40 mV were measured by eliciting responses with 3-s pulses from −120 mV to −40 mV. The time course of deactivation was determined from a biexponential fit of the tail currents. The hook of the tail current was not included in the exponential fitting procedure for best fit with the bi-exponential function. Time constants extracted from this analysis are summarized in Fig. 2B , showing that a 5-min application of E1S significantly decreased both the fast and slow time constants of the hERG-channel deactivation at most of the potentials, and the effect was not recovered 5 min after the wash-out of E1S (n = 8). These results indicate that E1S suppresses hERG currents by modulating the gating rather than by blocking the channel pore.
In this study, we found that physiological levels of E1S acutely suppress hERG currents as well as E2 does, but E1 and E3 do not affect hERG currents. Our concentration-dependent curve of E1S for the hERG suppression revealed that E1S is a very potent hERG modulator with the K d value of 0.03 nM, which is 20 times more potent than E2 (K d = 0.6 nM) (11) . Although E1S is ineffective on estrogen-receptor signaling, E1S is quantitatively the major circulating plasma estrogen in both women and men. The physiological plasma E1S level ranges from 0.5 -4.2 nM over a wide age range for women and men (13, 14) . Our data therefore demonstrate that circulating E1S may modulate hERG currents with the maximal extent in both women and men at any age. Although it is unlikely that circulating E1S contributes to the sex-difference of propensity for druginduced TdP, our data strongly suggest that the hERGchannel currents may be suppressed by E1S under physiological conditions in both women and men at any age.
A positive shift of the activation by E1S can explain the partial hERG suppression. No effect of E1S on I max of the activation suggests that E1S, like E2, is not a pore-blocker (11) . The experimental data in Fig. 1C (19.6 ± 2.9% hERG suppression by E1S) is very close to the calculated value of hERG suppression (18.7%) obtained from the values of V 1/ 2 and k in Table 1 , which accounts for the gating modification. This comparison suggests that E1S acts as a gating modifier of the hERG channel as well as E2, implying that E1S and E2 share, at least in part, the binding site on the channel. Influence of E2 on E1S bound channels is a subject for future studies.
A major finding in this paper is that E1S, which is generally thought to be an ineffective estrogen, suppresses hERG currents independently of estrogen receptors. Because there is increasing evidence of receptor-independent effects of estrogens (11, 15) , an impact of E1S, the quantitatively major circulating estrogen, on physiological function has to be considered not only in the heart but also in other tissues. 
